CG Oncology (CGON) to Release Earnings on Tuesday

CG Oncology (NASDAQ:CGON) is projected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect CG Oncology to post earnings of ($0.37) per share and revenue of $0.11 million for the quarter.

CG Oncology Trading Down 2.5 %

Shares of CGON stock opened at $27.05 on Monday. CG Oncology has a 1 year low of $23.91 and a 1 year high of $46.99. The firm’s 50 day moving average is $28.08 and its 200-day moving average is $32.15.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Friday, January 10th. TD Cowen initiated coverage on CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $55.00 price objective on shares of CG Oncology in a research report on Friday, March 7th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $66.00 target price on shares of CG Oncology in a research report on Friday, December 6th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, CG Oncology currently has an average rating of “Buy” and a consensus target price of $63.88.

Insider Buying and Selling at CG Oncology

In related news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.